Kalmente (Mometasone Furoate Anhydrous)

Mometasone furoate, the active ingredient in Kalmente, is a corticosteroid presented as a nasal spray for nasal use. It is indicated for the treatment of allergic rhinitis and nasal polyps in adults and children. GNH USA supplies Kalmente as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve symptoms of several upper‑respiratory conditions. Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. Nasal polyps: decreases polyp size and improves nasal airflow. Non‑allergic rhinitis: alleviates nasal obstruction and discharge.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleed) - Throat irritation or dryness - Cough - Altered taste or taste loss

Serious or Rare Side Effects: - Nasal septal perforation - Adrenal suppression with prolonged use - Elevated intra‑ocular pressure, cataracts or glaucoma - Severe allergic reaction (anaphylaxis) - Opportunistic fungal infection of the nasal passages - Systemic corticosteroid effects such as hyperglycaemia

Before using Kalmente, consider the following safety measures. - Pregnancy: consult a healthcare professional as safety data are limited. - Lactation: discuss potential risks with a physician before use while breastfeeding. - Elderly patients: monitor for systemic corticosteroid effects due to altered metabolism. - Chronic ocular disease: assess intra‑ocular pressure regularly during prolonged therapy. - Long‑term use: evaluate for signs of adrenal suppression or nasal mucosal atrophy. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate nasal spray can interact with other medications.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise systemic exposure. - Live vaccines: potential reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, ritonavir): may modestly increase exposure. - Nasal decongestants: may enhance local irritation. - Antihistamines: additive sedation is uncommon but monitor patient comfort.